Loading...
Loading...
Of the 3 tracked institutions holding HALO 0.25 03/01/27, 2 have a 3-year clone track record — 2 of them beat the S&P. Average holder's clone alpha: +8.3pt. It's a gauge of who owns the name, not just how many.
Alpha = the manager's 3-year clone return minus the S&P 500. A skilled roster is a stronger tell than a crowded one — though even skilled managers' edge doesn't reliably survive the 13F disclosure lag. Why →
Among the 3 tracked institutional investors we monitor, HALO 0.25 03/01/27 (HALOZYME THERAPEUTICS INC) is held with a combined value of $24.31M across 21,805,000 shares. The largest holder is CITADEL ADVISORS LLC with a position worth $13.32M. 1 fund increased its holdings. 1 fund reduced its position.
Total Institutional Value
$24.31M
Total Shares Held
21,805,000
Institutional Holders
3
Ranked by estimated dollars moved (share change × implied price). 13F data lags up to 45 days.
| # | Fund | Value↓ | Portfolio % | Change |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | $13.32M | 0.01% | -38.6% |
| 2 | Point72 Asset Management, L.P. | $8.36M | 0.01% | - |
| 3 | FMR LLC | $2.63M | 0.00% | +0.9% |
As of the latest SEC 13F filings, CITADEL ADVISORS LLC is the largest institutional holder of HALO 0.25 03/01/27 with a position worth $13.32M, representing 0.01% of their portfolio. In total, 3 institutional investors hold HALO 0.25 03/01/27 with a combined value of $24.31M.
Institutional investors hold $24.31M worth of HALO 0.25 03/01/27 stock across 3 positions. The largest institutional holder is CITADEL ADVISORS LLC with $13.32M in holdings.
A 13F filing is a quarterly report required by the SEC from institutional investment managers with over $100 million in assets. It discloses their holdings in U.S. equities. For HALO 0.25 03/01/27, these filings reveal which major funds are accumulating or reducing positions, providing insights into institutional sentiment.
Get notified when hedge funds change their HALO 0.25 03/01/27 positions.
